The relationship between URG4 and clinicopathologic parameters and its effect on two-year survival in gastric carcinoma

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2024-09-25 DOI:10.1016/j.tranon.2024.102122

Ethem Ömeroğlu

{"title":"The relationship between URG4 and clinicopathologic parameters and its effect on two-year survival in gastric carcinoma","authors":"Ethem Ömeroğlu","doi":"10.1016/j.tranon.2024.102122","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. The present study examined the relationship between Upregulated gene 4 (URG4) expression, an oncogene involved in the development of gastric carcinoma, and clinicopathologic parameters including Human epidermal growth factor receptor 2 (HER2) status. The study aimed to investigate the importance of URG4 as a prognostic factor for 2-year survival in GCs, which are usually in the advanced stage at the time of diagnosis and have a rapid course.</div></div><div><h3>Methods</h3><div>In 61 patients with GC, URG4 expression results in paraffin blocks were compared with the patients' clinicopathologic, 2-year survival, and HER2 results.</div></div><div><h3>Results</h3><div>Among the patients, 24 (39 %) had low URG4 scores (scores 0–4) and 37 (61 %) had high URG4 scores (scores 6–9). While the HER2 score was negative in 52 (85 %)patients, it was positive in 9 (15 %). URG4 expression values were significantly correlated with tumor (T) stage and lymphovascular invasion (LVI) (<em>p</em> < 0.005), whereas no significant correlation was determined between other pathological prognostic factors and HER2 status (<em>p</em> > 0.005). During the two-year period, 32 (52 %) patients survived and 29 (48 %) died. The mean duration of survival was 75.20 ± 35.22 weeks. A significant correlation was determined between URG4 values and survival and mortality results (<em>p</em> < 0.05).</div></div><div><h3>Conclusion</h3><div>We revealed a correlation (<em>p</em> < 0.005) between increased URG4 scores with increased T stage and LVI. We demonstrated an association between increased URG4 expression and survival time and mortality in patients with GC during the first two years of survival (<em>p</em> < 0.005) and URG4 and HER2 yielded similar results as prognostic factors in the survival of the patients URG4 is an essential oncogene in malignancies, especially in gastric GC, requiring further research and development in prognostic and therapeutic areas.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"50 ","pages":"Article 102122"},"PeriodicalIF":5.0000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002493","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. The present study examined the relationship between Upregulated gene 4 (URG4) expression, an oncogene involved in the development of gastric carcinoma, and clinicopathologic parameters including Human epidermal growth factor receptor 2 (HER2) status. The study aimed to investigate the importance of URG4 as a prognostic factor for 2-year survival in GCs, which are usually in the advanced stage at the time of diagnosis and have a rapid course.

Methods

In 61 patients with GC, URG4 expression results in paraffin blocks were compared with the patients' clinicopathologic, 2-year survival, and HER2 results.

Results

Among the patients, 24 (39 %) had low URG4 scores (scores 0–4) and 37 (61 %) had high URG4 scores (scores 6–9). While the HER2 score was negative in 52 (85 %)patients, it was positive in 9 (15 %). URG4 expression values were significantly correlated with tumor (T) stage and lymphovascular invasion (LVI) (p < 0.005), whereas no significant correlation was determined between other pathological prognostic factors and HER2 status (p > 0.005). During the two-year period, 32 (52 %) patients survived and 29 (48 %) died. The mean duration of survival was 75.20 ± 35.22 weeks. A significant correlation was determined between URG4 values and survival and mortality results (p < 0.05).

Conclusion

We revealed a correlation (p < 0.005) between increased URG4 scores with increased T stage and LVI. We demonstrated an association between increased URG4 expression and survival time and mortality in patients with GC during the first two years of survival (p < 0.005) and URG4 and HER2 yielded similar results as prognostic factors in the survival of the patients URG4 is an essential oncogene in malignancies, especially in gastric GC, requiring further research and development in prognostic and therapeutic areas.

查看原文本刊更多论文

胃癌 URG4 与临床病理参数的关系及其对两年生存率的影响

目的胃癌（GC）是全球癌症相关死亡的第三大原因。本研究探讨了上调基因 4（URG4）表达（一种参与胃癌发展的癌基因）与临床病理参数（包括人类表皮生长因子受体 2（HER2）状态）之间的关系。该研究旨在探讨URG4作为胃癌患者2年生存率预后因素的重要性，因为胃癌在诊断时通常处于晚期，病程较快。52例（85%）患者的HER2评分为阴性，9例（15%）为阳性。URG4表达值与肿瘤（T）分期和淋巴管侵犯（LVI）显著相关（p <0.005），而其他病理预后因素与HER2状态之间无显著相关性（p >0.005）。两年期间，32 例（52%）患者存活，29 例（48%）死亡。平均存活时间为（75.20 ± 35.22）周。结论我们发现 URG4 评分增加与 T 期和 LVI 增加之间存在相关性（p< 0.005）。URG4是恶性肿瘤（尤其是胃癌）中一种重要的癌基因，需要在预后和治疗领域进行进一步的研究和开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.